Three Seasons Wealth LLC Invests $1.17 Million in Exelixis, Inc. $EXEL

Three Seasons Wealth LLC acquired a new position in shares of Exelixis, Inc. (NASDAQ:EXEL) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 28,276 shares of the biotechnology company’s stock, valued at approximately $1,168,000.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Truist Financial Corp boosted its holdings in Exelixis by 1.1% during the second quarter. Truist Financial Corp now owns 22,292 shares of the biotechnology company’s stock worth $983,000 after buying an additional 250 shares during the last quarter. Police & Firemen s Retirement System of New Jersey boosted its stake in Exelixis by 0.3% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 102,581 shares of the biotechnology company’s stock worth $4,521,000 after acquiring an additional 274 shares during the last quarter. Plato Investment Management Ltd boosted its stake in Exelixis by 6.5% during the 2nd quarter. Plato Investment Management Ltd now owns 6,174 shares of the biotechnology company’s stock worth $271,000 after acquiring an additional 377 shares during the last quarter. Stratos Wealth Partners LTD. grew its holdings in Exelixis by 6.3% during the second quarter. Stratos Wealth Partners LTD. now owns 6,726 shares of the biotechnology company’s stock valued at $296,000 after purchasing an additional 399 shares during the period. Finally, Byrne Asset Management LLC increased its stake in Exelixis by 129.0% in the second quarter. Byrne Asset Management LLC now owns 710 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 400 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Price Performance

EXEL stock opened at $46.24 on Monday. The stock has a market capitalization of $12.40 billion, a P/E ratio of 19.51, a P/E/G ratio of 0.83 and a beta of 0.40. Exelixis, Inc. has a fifty-two week low of $31.90 and a fifty-two week high of $49.62. The business has a 50-day moving average of $41.82 and a 200-day moving average of $40.93.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, November 4th. The biotechnology company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.10. Exelixis had a return on equity of 31.06% and a net margin of 29.63%.The business had revenue of $597.76 million for the quarter, compared to analyst estimates of $590.04 million. During the same quarter last year, the firm earned $0.47 EPS. Exelixis’s revenue for the quarter was up 10.8% compared to the same quarter last year. Equities analysts expect that Exelixis, Inc. will post 2.04 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. Wolfe Research began coverage on shares of Exelixis in a research report on Tuesday, November 18th. They set a “peer perform” rating on the stock. Leerink Partners upgraded Exelixis from a “market perform” rating to an “outperform” rating and set a $48.00 target price on the stock in a report on Tuesday, October 21st. Stifel Nicolaus set a $43.00 target price on Exelixis in a research note on Wednesday, November 5th. Cowen reaffirmed a “buy” rating on shares of Exelixis in a research report on Wednesday, November 5th. Finally, Citigroup reiterated a “market outperform” rating on shares of Exelixis in a research report on Thursday, December 18th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eleven have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $45.74.

Insider Buying and Selling at Exelixis

In other Exelixis news, Director Stelios Papadopoulos sold 100,000 shares of Exelixis stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $43.55, for a total value of $4,355,000.00. Following the sale, the director directly owned 1,189,228 shares in the company, valued at approximately $51,790,879.40. The trade was a 7.76% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Mary C. Beckerle sold 24,622 shares of the business’s stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $41.93, for a total transaction of $1,032,400.46. Following the sale, the director directly owned 21,380 shares in the company, valued at $896,463.40. This trade represents a 53.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 245,235 shares of company stock worth $10,490,600. Company insiders own 2.85% of the company’s stock.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.